NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
02/24/2021
Back to search
Official data from USPTO
IDERA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
60
Latest update
06/19/2026
Trademark type
Word
Nice classes
5
Filing date
06/28/2005
Registration date
09/15/2009
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/24/2021
Last transaction
06/19/2026
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
06/02/2008
First use in commerce
06/02/2008
Drawing code
4
Owner type
03
Owner location
CAMBRIDGE, MA, US
Examiner
GAAFAR, SAMIR MICHAEL
Law office
M70
Current location
GENERIC WEB UPDATE
Holders and representatives
Holders
IDERA PHARMACEUTICALS, INC.
Hybridon, Inc.
Representatives
Rebecca E. McDougall Morgan, Lewis & Bockius LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medical therapeutic preparationsbiologically active modulatorsbiologically active immune modulatorsbiologically active antisense DNA or RNA compoundschemical modulators of gene expression working at DNA transcriptionRNA or translation processes; immunomodulatory oligonucleotidesingredients that enhance or induce an immune response as a component part in a pharmaceutical preparation; pharmaceutical and vaccine adjuvants to enhance the immune system response; pharmaceuticals for use in the treatment of viral and bacterial infectioninflammatory disorders and diseasesasthma or allergiescancerauto immune diseases and disorders and vaccine adjuvants to modulate the immune system; biologically active pharmaceutical compounds for use in the treatment of viral and bacterial infection or diseases associated with cellular gene expressions by preventing the production of disease associated proteins made by said infectious agents or cellular genes
Publications
History of USPTO decisions and trademark events.
60 publications found
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
02/24/2021
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
02/24/2021
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
02/22/2021
PR89
POST REGISTRATION ACTION MAILED - SEC. 8 & 9
08/24/2020
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
08/21/2020
REIN
REINSTATED
08/21/2020
PCGR
PETITION TO DIRECTOR GRANTED
08/21/2020
ERTI
TEAS RESPONSE TO PETITION INQUIRY LETTER
08/17/2020
PILM
PETITION INQUIRY LETTER ISSUED
07/29/2020
APET
ASSIGNED TO PETITION STAFF
07/28/2020
TPDR
TEAS PETITION TO DIRECTOR RECEIVED
04/06/2020
NCS8
NOTICE OF CANCELLATION SEC. 8 EMAILED
03/27/2020
C8.T
CANCELLED SEC. 8 (10-YR)
03/26/2020
PR89
POST REGISTRATION ACTION MAILED - SEC. 8 & 9
09/25/2019
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
09/24/2019
E89R
TEAS SECTION 8 & 9 RECEIVED
09/16/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/23/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/23/2019
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
09/15/2018
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
10/27/2015
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
10/27/2015
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
10/27/2015
E815
TEAS SECTION 8 & 15 RECEIVED
09/10/2015
R.PR
REGISTERED-PRINCIPAL REGISTER
09/15/2009
REGV
LAW OFFICE REGISTRATION REVIEW COMPLETED
08/11/2009
ALIE
ASSIGNED TO LIE
08/10/2009
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
07/31/2009
SUPC
STATEMENT OF USE PROCESSING COMPLETE
07/28/2009
EX5G
SOU EXTENSION 5 GRANTED
07/28/2009
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
07/28/2009
IUAF
USE AMENDMENT FILED
07/06/2009
EXT5
SOU EXTENSION 5 FILED
07/06/2009
EEXT
SOU TEAS EXTENSION RECEIVED
07/06/2009
EISU
TEAS STATEMENT OF USE RECEIVED
07/06/2009
EX4G
SOU EXTENSION 4 GRANTED
01/15/2009
EXT4
SOU EXTENSION 4 FILED
01/15/2009
EEXT
SOU TEAS EXTENSION RECEIVED
01/15/2009
EX3G
SOU EXTENSION 3 GRANTED
07/23/2008
EXT3
SOU EXTENSION 3 FILED
07/23/2008
EEXT
SOU TEAS EXTENSION RECEIVED
07/23/2008
EX2G
SOU EXTENSION 2 GRANTED
02/08/2008
EXT2
SOU EXTENSION 2 FILED
01/23/2008
EEXT
SOU TEAS EXTENSION RECEIVED
01/23/2008
EX1G
SOU EXTENSION 1 GRANTED
07/03/2007
EXT1
SOU EXTENSION 1 FILED
07/03/2007
EEXT
SOU TEAS EXTENSION RECEIVED
07/03/2007
NOAM
NOA MAILED - SOU REQUIRED FROM APPLICANT
01/23/2007
PUBO
PUBLISHED FOR OPPOSITION
10/31/2006
NPUB
NOTICE OF PUBLICATION
10/11/2006
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
09/15/2006
ALIE
ASSIGNED TO LIE
09/08/2006
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/05/2006
ACEC
AMENDMENT FROM APPLICANT ENTERED
08/15/2006
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/28/2006
PAPER RECEIVED
07/28/2006
GNRT
NON-FINAL ACTION E-MAILED
01/30/2006
CNRT
NON-FINAL ACTION WRITTEN
01/30/2006
DOCK
ASSIGNED TO EXAMINER
01/19/2006
NWAP
NEW APPLICATION ENTERED
07/05/2005
Continuous trademark protection
Get notified about every new filing that threatens IDERA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.